Composition to mitigate radiation injury and application thereof
Patent Information
- Application Number
- IN202111027432
- Authority / Receiving Office
- IN · IN
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2021-06-18
- Publication Date
- 2026-10-06
AI Technical Summary
Current methods for addressing radiation injuries, such as those caused by exposure to ionizing radiation, are inadequate in enhancing hematopoietic cell survival, proliferation, and differentiation, and do not effectively mitigate the effects of radiation on bone marrow stem cells.
A composition comprising lithium chloride (1-20 mM), a peptide with the amino acid sequence GRKKRRQRRRPPQCKLSNEPHLR (GR23), and ascorbic acid, which works synergistically to improve hematopoietic cell survival by neutralizing Bax protein and increasing Bcl-2 levels, facilitating cell homing, self-renewal, and differentiation in bone marrow.
The composition significantly enhances hematopoietic cell survival, reduces DNA damage, and improves bone marrow engraftment, leading to effective treatment of radiation injuries and potential applications in radiation exposure scenarios, including nuclear disasters and therapy.
Abstract
Description
FIELD OF THE INVENTION
[001] The present disclosure relates broadly to the field of regenerative medicine orhematology. In particular, the present disclosure discloses a composition for enhancingthe in-vitro and in-vivo hematopoietic cell survival capability in irradiated conditions.BACKGROUND OF THE INVENTION
[002] On exposure to extensive radiation for a short span of time, an organismgenerally gets affected with a disease called radiation sickness, and the losses incurredto such an organism are called radiation injuries. Such injuries or damage are generallycaused by radiation emitted from x-rays such as those used in diagnostic equipments,γ-rays such as those emitted from radioactive materials or from numerous othersources. The severity of radiation injury caused by exposure to strong radiation dependsupon the surface area exposed and the strength of radiation. In humans, organs likebone marrow, intestine, thyroid gland, liver, lungs, etc., generally gets affected bystrong radiation exposure. Radiation injury may range from less serious injuries suchas radiation dermatitis to more serious injuries such as those causing vomiting, bonemarrow failure, and intestinal death.
[003] The full body exposure to the strong radiation may lead to loss of replenishingstem cells in most of the organs, wherein bone marrow and intestine are highly sensitiveorgans. Even on severe infrared exposure, the hematopoietic stem cells responsible forblood formation in the bone marrow undergo cell death or apoptosis due to damagecaused to their deoxyribonucleic acid. Although, radiation exposure leads to variousother similar problems as per the field of art is concerned, but there are hardly anypromising prevention or treatments strategies available to address afore-mentionedhealth problems.
[004] For instance, the Patent AU2002309615B2, discloses a method for theprevention, reduction or treatment of radiation injury caused by ionising radiation byorally administering an oral composition. The said patent further relates to the said oralcomposition, wherein the composition comprises an amount of one or morecompounds effective to regulate at least one of cell differentiation and cell proliferationwhich is effective, and an effective amount of one or more antioxidants.
[005] The Patent US7795226B2, relates to a drug development against acute radiationinjury caused by exposure to high-energy electromagnetic waves (X-rays, gamma rays)or particles (alpha particles, beta particles, neutrons). The said patent further disclosesa method of treating radiation injury by providing a subject having an acute radiationinjury with a pharmaceutical composition, said composition comprising, a peptideconsisting of the amino acid sequence "AQGV" and a pharmaceutically acceptableexcipient.
[006] There are various other conventional compositions and methods available in theart to cure or prevent or mitigate the health problems developed on extensive radiationexposure. Decontamination after radiation exposure eliminates about 90 percent ofexternal contamination, thereby lowering the risk of spread of radioactive materials andinternal contamination from inhalation, ingestion or open wounds. The alternativetreatment strategies based on the treatment of internal contamination, involving the useof potassium iodide, prussian blue, diethylenetriamine pentaacetic acid (DTPA), or thelike for the prevention of chances of further damage to the body organs by removal ofradioactive particles, are also available (Mayoclinic.org. 2020. Radiation Sickness -Diagnosis And Treatment - Mayo Clinic. [online] Available at:<https: / / www.mayoclinic.org / diseases-conditions / radiation-sickness / diagnosistreatment / drc-20377061> [Accessed 10 November 2020]).
[007] However, despite the ongoing research in order to develop various methods tocure radiation injuries, there still persists a dearth in providing a better and effectivesolution to the problems associated with radiation exposure, which may show increasedhoming of cells to bone marrow, their self-renewal, proliferation, anddifferentiation at a cut above to the present conventional methods.SUMMARY OF THE INVENTION
[008] These and other features, aspects, and advantages of the present subject matterwill be better understood with reference to the following description and appendedclaims. This summary is provided to introduce a selection of concepts in a simplifiedform. This summary is not intended to identify key features or essential features of theclaimed subject matter, nor is it intended to be used to limit the scope of the claimedsubject matter.
[009] In an aspect of the present disclosure, there is provided a compositioncomprising: (a) lithium chloride having a concentration in the range of 1-20 mM withrespect to the composition; (b) a peptide having an amino acid sequence as set forth inSEQ ID NO: 1; and (c) ascorbic acid.
[010] In another aspect of the present disclosure, there is provided a process forpreparing a composition comprising: (a) lithium chloride having a concentration in therange of 1-20 mM with respect to the composition; (b) a peptide having an amino acidsequence as set forth in SEQ ID NO: 1; and (c) ascorbic acid, said process comprising:contacting lithium chloride having a concentration in the range of 1-20 mM withrespect to the composition, the peptide, and ascorbic acid, to obtain the composition.
[011] In an aspect of the present disclosure, there is provided a compositioncomprising: (a) lithium chloride having a concentration in the range of 1-20 mM withrespect to the composition; (b) a peptide having an amino acid sequence as set forth inSEQ ID NO: 1; and (c) ascorbic acid, wherein the composition mitigates the effect ofnuclear radiation.BRIEF DESCRIPTION OF ACCOMPANYING DRAWINGS
[012] The following drawings form a part of the present specification and are includedto further illustrate aspects of the present disclosure. The disclosure may be betterunderstood by reference to the drawings in combination with the detailed descriptionof the specific embodiments presented herein.
[013] Figure 1a depicts a gel picture of the Coomassie blue stained SDS-PAGEhaving lanes, L1, L2, L3, L4 and L5 corresponding to protein ladder, Bcl-2 protein,Bax protein, Bcl-2 and Bax proteins and immunoprecipitation with Bcl-2 antibodyshowing co-immunoprecipitated (CoIP) band of Bcl-2-Bax proteins, respectively;Figure 1b depicts a gel picture of SDS-PAGE showing bands for all concentrations ofGR23 peptide including 0.025μM, 0.25μM, 2.5μM and 5μM for the mixtures ofrespective GR23 concentrations with incubated with Bcl-2 and Bax protein to releaseBcl-2 (21kD) from the complex, in accordance with an embodiment of the presentdisclosure.
[014] Figure 2 depicts the bioluminescence imaging of four mice samples to assessthe GR23-FITC biodistribution at post 30 minutes and 2 hours from the time of GR23-FITC treatment, in accordance with an embodiment of the present disclosure.
[015] Figure 3a depicts the bioluminescence imaging of three mice femur samples toassess the GR23-FITC biodistribution at post 3 hours from the time of GR23-FITCtreatment; Figure 3b depicts the fluorometric analysis of the mouse bone marrowsample indicating a significant distribution of GR23-FITC in bone marrow cell, inaccordance with an embodiment of the present disclosure.
[016] Figure 4a depicts the bar chart of the absorbance at 570nm of Vitamin A testedfor 0M, 10-5M and 10-6M dosage concentrations in KG1a cells at 0, 24 and 48 hoursfrom the treatment; Figure 4b depicts the bar chart for toxicity assessment of ascorbicacid dosage at the concentrations of 2μg / ml, 20μg / ml and 200μg / ml in KG1a cells, inaccordance with an embodiment of the present disclosure.
[017] Figure 5a shows the comet assay results, which was performed to assess theDNA damage for different samples including control, 4Gy IR, LiCl, ascorbic acid,GR23, Vitamin A, Li- ascorbic acid, Li-GR23, ascorbic acid-GR23, GR23-Vitamin A,Li-GR23-Vitamin A, composition; Figure 5b shows the box plot of percentage of tailDNA in analyzed comets (25-30 in number) in each sample at the end of 24 hours, inaccordance with an embodiment of the present disclosure.
[018] Figure 6 depicts the semi-log plot of irradiated KGla cells treated withcomposition (Li+GR23+AA), (Li+GR23+Vitamin A) and control wherein thetreatment of cells with composition (Li+GR23+AA) significantly improved thesurviving fraction of cells at 4Gy, in accordance with an embodiment of the presentdisclosure.
[019] Figure 7 depicts the survival kinetics of 7.5Gy irradiated mice treated withcomposition wherein the composition rescued all the mice from imminent death with100% survivability, in accordance with an embodiment of the present disclosure.
[020] Figure 8 depicts the SEM micrograph of KG1a cells coated with A-F conjugateat 10X and 40X magnifications wherein the cell surface morphology changed fromgranular to smooth after coating, in accordance with an embodiment of the presentdisclosure.
[021] Figure 9a depicts the images of green coloured bone marrow cell membraneand blue coloured nucleus showing successful labelling with PKH green dye and 4',6-diamidino-2-phenylindole (DAPI) respectively; Figure 9b depicts the bioluminescenceimaging of the femur bone, which was isolated to check PKH fluorescence emanatingfrom bone marrow after 24 hours of cell transplantation; Figure 9c depicts thefluorometric analysis indicated significantly higher number of alginate and fibronectincoated cells reaching to bone marrow in comparison to cells without coating and thecontrol respectively, in accordance with an embodiment of the present disclosure.
[022] Figure 10 depicts the events of sequential administration of compositionconstituents for enhancing bone marrow engraftment, in accordance with anembodiment of the present disclosure.
[023] Figure 11a depicts the survival curve of the mice based on survival percentagemonitored for 30 days post treatment, for control group, 7.5Gy irradiated group, bonemarrow transplantation group (BMT) group, alginate and fibronectin conjugate (AF)coated bone marrow transplantation group (BMT) group and LiCl+GR23+AF coatedBMT group; Figure 11b depicts the images of the sample mice receiving multi-therapytreatment with disclosed composition did not show any abnormal growth up to 90 daysindicating non-tumorigenicity of the followed regimen, in accordance with anembodiment of the present disclosure.
[024] Figure 12a depicts the histology of jejunum, liver, lung and kidney in control,irradiated and treatment group after 5 days; Figure 12b depicts the histology ofjejunum, liver, lung and kidney in control, irradiated and treatment group after 10 days;Figure 12c depicts the histology of jejunum, liver, lung and kidney in control, irradiatedand treatment group after 60 days, in accordance with an embodiment of the presentdisclosure.
[025] Figure 13 depicts the expression of haematological parameters measured after5, 10, 30 and 60 days after infrared exposure, in accordance with an embodiment of thepresent disclosure.DETAILED DESCRIPTION OF THE INVENTION
[026] Those skilled in the art will be aware that the present disclosure is subject tovariations and modifications other than those specifically described. It is to beunderstood that the present disclosure includes all such variations and modifications.The disclosure also includes all such steps, features, compositions, and compoundsreferred to or indicated in this specification, individually or collectively, and any andall combinations of any or more of such steps or features.Definitions
[027] For convenience, before further description of the present disclosure, certainterms employed in the specification, and examples are delineated here. Thesedefinitions should be read in the light of the remainder of the disclosure and understoodas by a person of skill in the art. The terms used herein have the meanings recognizedand known to those of skill in the art, however, for convenience and completeness,particular terms and their meanings are set forth below.
[028] The articles "a", "an" and "the" are used to refer to one or to more than one (i.e.,to at least one) of the grammatical object of the article.
[029] The terms "comprise" and "comprising" are used in the inclusive, open sense,meaning that additional elements may be included. It is not intended to be construed as"consists of only".
[030] Throughout this specification, unless the context requires otherwise the word"comprise", and variations such as "comprises" and "comprising", will be understoodto imply the inclusion of a stated element or step or group of element or steps but notthe exclusion of any other element or step or group of element or steps.
[031] The term "including" is used to mean "including but not limited to". "Including"and "including but not limited to" are used interchangeably.
[032] The term "composition or disclosed composition" used herein refers to thecomposition as disclosed in the present disclosure, wherein the said compositioncomprising: (a) lithium chloride having a concentration in the range of 1-20 mM withrespect to the composition; (b) a peptide having an amino acid sequence as set forth inSEQ ID NO: 1; and (c) ascorbic acid.
[033] The term "GR23 or GR23 peptide", refers to a Bax Antagonist Peptide (BAP)having an amino acid sequence as set forth in SEQ ID NO: 1.Sequences used in the present disclosure:
[034] SEQ ID NO: 1 depicts the amino acid sequence of peptide GR23.GRKKRRQRRRPPQCKLSNEPHLR
[035] Unless defined otherwise, all technical and scientific terms used herein have thesame meaning as commonly understood by one of ordinary skill in the art to which thisdisclosure belongs. Although any methods and materials similar or equivalent to thosedescribed herein can be used in the practice or testing of the disclosure, the preferredmethods, and materials are now described. All publications mentioned herein areincorporated herein by reference.
[036] As discussed in the background section of the present disclosure, there arevarious conventional methods available to cure radiation injuries. However, the saidmethods including various pharmaceutical compositions and treatment strategies toeither elevate the replenishment of stem cells or to prevent the internal / externalcontamination from the extensive radiation exposure. In the events of celldeath / apoptosis occurring on the radiation exposure, anti-apoptotic protein, Bcl-2, andpro-apoptotic protein, Bax, play an important role in regulating cell death. In thepresent disclosure, a Bax Antagonist Peptide (BAP) named GR23, was employed alongwith LiCl wherein GR23 peptide neutralized Bax protein and increased cellularconcentration of free Bcl-2 in immunoprecipitation assay so that Bcl-2 could regulatemitochondrial transmembrane potential and subsequent events of cell death. Thecomposition consisting of LiCl, GR23 and ascorbic acid would likely to decreaseradiation injury in-vitro and in-vivo by improving hematopoietic cells survival.Therefore, the biodistribution of in vivo injected GR23 peptide in bone marrow,suggesting it to be a potential molecule for protecting bone marrow stem cells. Thepresent disclosure discloses a combination of antagonist peptide GR23 and LiClshowing synergistic effects for decrease in the apoptosis of effected cell population bythe radaition exposure. Further, as per the present disclosure, sequential administrationof individual components including LiCl, GR23 and ascorbic acid could also be usedin the cell transplantation studies for enhancement in bone marrow (BM) reconstitutionafter radiation apalasia. The present disclosure provides solution to the existingproblems in the literature by providing composition comprising: (a) lithium chloridehaving a concentration in the range of 1-20 mM with respect to the composition; (b) apeptide having an amino acid sequence as set forth in SEQ ID NO: 1; and (c) ascorbicacid, which facilitated homing of cells to bone marrow, their self-renewal, proliferationand differentiation.
[037] Ascorbic acid is widely distributed in human diet and has been reported toscavenge oxygen species and prevent cell damage. It can also quench free radicalsgenerated by irradiation. The role of ascorbic acid in the present composition would beto mitigate radiation damage following acute / chronic exposures and as prophylaxisagainst potential radiation exposures. Moreover, it is likely to degrade the cellular AFshielded coating bone marrow cells after their targeting to bone marrow.
[038] LiCl is a clinically used drug for bipolar disorders. Mechanistically, it is aglycogen synthase kinase 3 beta (GSK3β) inhibitor, it exerts multifaceted effects onorgan systems. Hematological effects of LiCl includes increase in megakaryocytes orplatelet production, monocytes or macrophages of reticuloendothelial system,neutrophils and its bactericidal effect, circulation of CD34+ cells, granulocyte-colonystimulating factor (G-CSF), proliferation of pluripotential stem cells and CSFproduction by bone marrow mononuclear cells(MNC) and peripheral blood. Apart fromhematological effects, LiCl also improves neurogenesis, vessel formation and reducesstress. LiCl also displays radioprotective capability exerted due to the inhibition ofGSK3β, p53 and Bax proteins. Therefore, due to afore-mentioned reasons LiCl wasemloyed in the composition as dislcosed herein to mitigate radiation injury
[039] In an embodiment of the present disclosure, there is provided a compositioncomprising: (a) lithium chloride having a concentration in the range of 1-20 mM withrespect to the composition; (b) a peptide having an amino acid sequence as set forth inSEQ ID NO: 1; and (c) ascorbic acid. In another embodiment of the present disclosure,lithium chloride has a concentration in the range of 1-18 mM with respect to thecomposition. In yet another embodiment of the present disclosure, lithium chloride hasa concentration in the range of 1.5-16.5 mM with respect to the composition.
[040] In an embodiment of the present disclosure, there is provided a compositioncomprising: (a) lithium chloride having a concentration in the range of 2-15 mM withrespect to the composition; (b) a peptide having an amino acid sequence as set forth inSEQ ID NO: 1; and (c) ascorbic acid. In another embodiment of the present disclosure,lithium chloride has a concentration in the range of 2-10 mM with respect to thecomposition.
[041] In an embodiment of the present disclosure, there is provided a compositioncomprising: (a) lithium chloride having a concentration in the range of 1-20 mM withrespect to the composition; (b) a peptide having an amino acid sequence as set forth inSEQ ID NO: 1; and (c) ascorbic acid, wherein the peptide is having a concentration inthe range of 1-30 μM with respect to the composition. In another embodiment of thepresent disclosure, the peptide has a concentration in the range of 1.5-25 μM withrespect to the composition. In yet another embodiment of the present disclosure, thepeptide has a concentration in the range of 1.5-22 μM with respect to the composition.
[042] In an embodiment of the present disclosure, there is provided a compositioncomprising: (a) lithium chloride having a concentration in the range of 1-20 mM withrespect to the composition; (b) a peptide having an amino acid sequence as set forth inSEQ ID NO: 1; and (c) ascorbic acid, wherein the peptide is having a concentration inthe range of 1.5-20 μM with respect to the composition.
[043] In an embodiment of the present disclosure, there is provided a compositioncomprising: (a) lithium chloride having a concentration in the range of 1-20 mM withrespect to the composition; (b) a peptide having an amino acid sequence as set forth inSEQ ID NO: 1; and (c) ascorbic acid having a concentration in the range of 0.05M-1Mwith respect to the composition. In another embodiment of the present disclosure,ascorbic acid has a concentration in the range of 0.1M-0.96M with respect to thecomposition.
[044] In an embodiment of the present disclosure, there is provided a compositioncomprising: (a) lithium chloride having a concentration in the range of 1-20 mM withrespect to the composition; (b) a peptide having an amino acid sequence as set forth inSEQ ID NO: 1; and (c) ascorbic acid having a concentration in the range of 0.1M-0.5Mwith respect to the composition.
[045] In an embodiment of the present disclosure, there is provided a compositioncomprising: (a) lithium chloride having a concentration in the range of 1-20 mM withrespect to the composition; (b) a peptide having an amino acid sequence as set forth inSEQ ID NO: 1, wherein the peptide is having a concentration in the range of 1-30 μMwith respect to the composition; and (c) ascorbic acid having a concentration in therange of 0.05M-1M with respect to the composition.
[046] In an embodiment of the present disclosure, there is provided a process forpreparing the composition comprising: (a) lithium chloride having a concentration inthe range of 1-20 mM with respect to the composition; (b) a peptide having an aminoacid sequence as set forth in SEQ ID NO: 1; and (c) ascorbic acid, said processcomprising: contacting lithium chloride having a concentration in the range of 1-20mM with respect to the composition, the peptide, and ascorbic acid, to obtain thecomposition.
[047] In an embodiment of the present disclosure, there is provided a process forpreparing the composition comprising: (a) lithium chloride having a concentration inthe range of 1-20 mM with respect to the composition; (b) a peptide having an aminoacid sequence as set forth in SEQ ID NO: 1 and a concentration in the range of 1-30μM with respect to the composition; and (c) ascorbic acid having a concentration in therange of 0.05M-1M with respect to the composition, said process comprising:contacting lithium chloride having a concentration in the range of 1-20 mM withrespect to the composition, the peptide, and ascorbic acid, to obtain the composition.
[048] In an embodiment of the present disclosure, there is provided a process forpreparing the composition comprising: (a) lithium chloride having a concentration inthe range of 1-20 mM with respect to the composition; (b) a peptide having an aminoacid sequence as set forth in SEQ ID NO: 1; and (c) ascorbic acid, said processcomprising: contacting lithium chloride having a concentration in the range of 1-20mM with respect to the composition, the peptide, and ascorbic acid, is done at atemperature in the range of 2-6ºC, to obtain the composition. In another embodimentof the present disclosure, contacting lithium chloride having a concentration in therange of 1-20 mM with respect to the composition, the peptide, and ascorbic acid isdone at a temperature of 4ºC, to obtain the composition.
[049] In an embodiment of the present disclosure, there is provided a process forpreparing the composition comprising: (a) lithium chloride having a concentration inthe range of 1-20 mM with respect to the composition; (b) a peptide having an aminoacid sequence as set forth in SEQ ID NO: 1 and a concentration in the range of 1-30μM with respect to the composition; and (c) ascorbic acid having a concentration in therange of 0.05M-1M with respect to the composition, said process comprising:contacting lithium chloride having a concentration in the range of 1-20 mM withrespect to the composition, the peptide, and ascorbic acid, is done at a temperature inthe range of 2-6ºC, to obtain the composition.
[050] In an embodiment of the present disclosure, there is provided a compositioncomprising: (a) lithium chloride having a concentration in the range of 1-20 mM withrespect to the composition; (b) a peptide having an amino acid sequence as set forth inSEQ ID NO: 1; and (c) ascorbic acid, wherein the composition mitigates the effect ofnuclear radiation.
[051] In an embodiment of the present disclosure, there is provided a compositioncomprising: (a) lithium chloride having a concentration in the range of 1-20 mM withrespect to the composition; (b) a peptide having an amino acid sequence as set forth inSEQ ID NO: 1 and concentration in the range of 1-30 μM with respect to thecomposition; and (c) ascorbic acid having a concentration in the range of 0.05M-1Mwith respect to the composition, wherein the composition mitigates the effect of nuclearradiation.
[052] Although the subject matter has been described with reference to specificembodiments, this description is not meant to be construed in a limiting sense. Variousmodifications of the disclosed embodiments, as well as alternate embodiments of thesubject matter, will become apparent to persons skilled in the art upon reference to thedescription of the subject matter. It is therefore contemplated that such modificationscan be made without departing from the spirit or scope of the present subject matter asdefined.EXAMPLES
[053] The disclosure will now be illustrated with working examples, which is intendedto illustrate the working of disclosure and not intended to take restrictively to implyany limitations on the scope of the present disclosure. Unless defined otherwise, alltechnical and scientific terms used herein have the same meaning as commonlyunderstood to one of ordinary skill in the art to which this disclosure belongs. Althoughmethods and materials similar or equivalent to those described herein can be used inthe practice of the disclosed methods and compositions, the exemplary methods,devices and materials are described herein. It is to be understood that this disclosure isnot limited to particular methods, and experimental conditions described, as suchmethods and conditions may vary.MATERIALS REQUIRED
[054] Chemicals and Reagents:
[055] The chemicals including IMDM, DMEM, FBS, LiCl, ascorbic acid, Vitamin A(Retinol), low melting point agarose, normal meting point agarose, methyl cellulose,and others as used herein were procured form M / s Sigma Aldrich, USA. Thecomposition as disclosed in the present disclosure, was prepared by mixing 10mMLiCl, 2.5μM GR23 and 20μg ascorbic acid for in-vitro treatment, and for in-vivoexperiments, 2mM LiCl, 3mg / kg body weight GR23 and 2.5mg / ml ascorbic acid wereused. Vitamin A (1 x10-6 M) was used as a surrogate (negative control) to ascorbic acidfor in-vitro analysis to observe whether it can replace ascorbic acid in the composition.GR23 peptide having an amino acid sequence as set forth in SEQ ID NO: 1, wascommercially synthesized using the service provided by M / s Link Biotech.
[056] Cell culture:
[057] For the purpose of in-vitro studies, KG1a cells were obtained from NationalCenter for Cell Science, Pune. The said cells were maintained in Iscove's ModifiedDulbecco's Medium (IMDM) containing 10% FBS and antibiotics.
[058] Animal samples:
[059] Eight to ten weeks old BALB / c mice weighing 26gm maintained at standardlaboratory conditions, fed with standard food pellet and water ad libitun, were used forthe study. The animals were housed in polypropylene cages bedded with sterilized ricehusk under the controlled environmental conditions of 12 hours alternating dark andlight cycle at temperature of 24±2°C. The experiments were conduted strictly adheringto the guidelines of the Institutional Animal Ethics Committee (IAEC sanction no.INM / IAEC / 16 / 02, Dated: 24 / 02 / 16). Each experiment was performed 2-3 times with5-6 mice in each group.Example 1Immunoprecipitation
[060] Immunoprecipitation was performed for precipitating Bcl-2 protein out ofsolution using an antibody that specifically binds to that Bcl-2 protein. For theimmunoprecipitation assay, combination of Bcl-2 and Bax pure proteins in 1:1 ratio(in a quantity of 1-10μg each) in 1ml of phosphate buffered saline (PBS) with0.025μM, 0.25μM, 2.5μM and 5μM of GR23 peptide (SEQ ID NO: 1) and withoutGR23 peptide were tested. The said solutions were incubated for 1 hour at roomtemperature (RT) to make Bcl-2-Bax hetrodimeric complex. After incubation at roomtemperature, 2μg of Bcl-2 antibody was added to the mixtures and followed byincubation for 1-2 hours at 4°C. The incubation at 4°C was further followed by theaddition of 20μl of resuspended volume of protein A / G Plus agarose beads. Theprepared mixtures were left for overnight incubation at 4°C on a rocker platform. Forall the mixtures, the immunoprecipitate was then collected by centrifugation at2500rpm for 5 minutes at 4°C. The supernatant obtained after centrifugation wasdiscarded and the pellet was washed 3-4 times with phosphate buffered saline (PBS),and after each time of washing of pellet the centrifugation step was repeated. Afterthe final centrifugation, the supernantant was discarded and the pellet wasresuspended in 30μl of 1X protein electrophoresis buffer. The prepared samples werethen boiled for 2-3 minutes and analyzed by sodium dodecyl sulfate-polyacrylamidegel electrohporesis (SDS-PAGE).
[061] The Bcl-2-Bax heterodimerization regulates the fate of cell survival as the higherconcentration of Bcl-2 upregulates survival by neutralizing the whole of intracellularBax protein and maintains mitochondrial transmembrane potential, which regulates theflux of ions through mitochondrial transmembrane pore. The apoptotic signal uponinfrared (IR) exposure activates transcription of Bax through p53 protein. The increasein number of Bax protein disrupts mitochondrial transmembrane potential byneutralizing all the Bcl-2 molecules, thereby leading to cell death. In theimmunoprecipitation assay as conducted herein, it was observed that the presence ofGR23 peptide releases Bcl-2 from Bax clutches, which was detected as free protein, asshown in Figure 1. Consequently, the intracellular presence of GR23, therefore,improves the cell survival by interacting with Bax protein. The Figure 1a depicts a gelpicture of the Coomassie blue stained SDS-PAGE having lanes, L1, L2, L3, L4 and L5corresponding to protein ladder, Bcl-2 protein, Bax protein, Bcl-2 and Bax proteins andimmunoprecipitation with Bcl-2 antibody showing co-immunoprecipitated (CoIP)band of Bcl-2-Bax proteins., respectively. Further, referring to Figure 1b, it can beobserved that different concentration of GR23 peptide was incubated with Bcl-2 andBax protein to release 21kD of Bcl-2 from the complex, and it was found out that at allconcentration of GR23 peptide including 0.025μM, 0.25μM, 2.5μM and 5μM, freeBcl-2 was detected in SDS-PAGE.
[062] Hence, it is concluded from the results that the use of GR23 peptide decreasesthe Bcl-2-Bax heterodimerisation, thereby improving the cell survivability.Example 2Biodistribution of FITC labelled GR23 peptide
[063] To study the biodistribution of FITC-labelled GR23 peptide, bioluminescenceimaging technique was employed in the present disclosure. The present experimentinvolved the use of BALB / c mice from the animal husbandy, and the experiment wasperformed 2-3 times with 5-6 mice in each group. Before conduting the mice survivalstudies, the distribution of FITC labelled GR23 was evaluated, especially in bonemarrow, by bioluminescence imaging (BLI). BLI allows the non-invasive study ofbiological processes in small laboratory animals like rats and mice.
[064] BALB / c mice were intravenously injected with 100μl of GR23-FITC preparedfrom the stock solution of 1.18mg / ml. Thereafter, mice were intraperitoneally injectedwith thiopentone anesthetic of 50mg / kg body weight. Fluorescence images wereobtained with Optical Imaging Scanner in-vivo F Pro (M / s BRUKER). BLI indicatedthe successful distribution of GR23 in the bone marrow and increased targeting of cellsto bone marrow, which improved the survivability of resident / transplanted stem cells.Four conditions are depicted in Figure 2, including blank (which was treated with salineonly) and GR23-FITC at post 30 minutes and 2 hours from the time of treatment,wherein red color indicates one of the highest concentrations of GR23 distributed in aparticular organ: brain, heart, lungs, kidney and spleen. In Figure 2, the color intensityscale indicates the lowest concentration of the GR23 peptide as black and the highestconcentration as white. Bioluminescence imaging (BLI) after 30 minutes of treatmentshowed GR23 distribution in brain, heart, lungs, kidney, and spleen as depicted inFigure 2. After 2h, GR23 was redistributed to heart, and most of it was detected inkidney, indicating its clearance from the body. After imaging, mice were sacrificed bycervical dislocation under anesthesia and femur bone was removed for its opticalimaging. For this purpose, the femur bones extracted from difference mice are denotedas BM1 and BM2. Both BM1 and BM2 are the femur bones extracted from differentmice give the same treatment. These are duplicates for the GR23-FITC peptide injectedmice. Bioluminescence imaging (BLI) of the femur bone of mice BM1 and BM2 wasobserved against control (blank), wherein higher color intensity was observed in femurbone of both the mice samples (BM1 and BM2) with respect to control as shown inFigure 3a. In Figure 3a, the black and the white colour showed the lowest and thehighest concentrations of the GR23 peptide.
[065] Post femur imaging, bone marrow cells were flushed with PBS in a petridishusing an insulin syringe. The bone marrow cells were then washed with PBS and thenfixed with 1% paraformaldehyde for 20 minutes at 4°C. Fixed cells were washed withPBS by centrifugation at 300g for 5 minutes. This was followed by fluorimetricanalysis of cells as shown in Figure 3b, wherein femur bone of GR23-FITC injectedmice (BM1 and BM2) showed higher fluorescence as compared to control after 3 hoursof treatment. In addition, the fluorimetric analysis also revealed a significantdistribution of GR23-FITC in the bone marrow.Example 3Toxicity studies of Vitamin A and Ascorbic acid
[066] To find out a window of non-toxic concentration of ascorbic acid to be used incomposition for preventing radiation injuries, 1 x 105 KG1a cells were treated with 2,20, and 200μg of ascorbic acid in 100μl of IMDM medium containing 10% fetal bovineserum. After 24 hours of incubation at 37°C in 5% CO2 atmosphere, the viability ofcells was evaluated by Prestoblue reagent. Similarly, the non-toxic concentration ofVitamin A (Retinol) was identified. 1x106 KG1a cells were treated with 10-6 M and 10-5 M of Retinol in IMDM medium containing 10% fetal bovine serum. The viability ofcells was evaluated at 0 hour, 24 hours and 48 hours of incubation at 37°C in 5% CO2atmosphere by Prestoblue reagent. Prestoblue is a ready-to-use reagent for rapidlyevaluating the viability and proliferation of cells as it is readily reduced bymetabolically active cells providing a quantitative measure of viability and cytotoxicityin a time period of 10 minutes. After incubation, 10μl of prestoblue reagent (10X) wasdirectly added to the cells in the culture medium. The reaction was incubated for≥10min at 37°C. Thereafter, the absorbance of culture medium was measured at570nm.
[067] The results of prestoblue assay as performed for the toxicity assessment ofvitamin A (retinol) and vitamin C (ascorbic acid) were then evaluated. Figure 4a showsthe results of the toxicity studies conducted with vitamin A at 0M, 10-5M and 10-6Mdosage concentrations in KG1a cells at 0, 24 and 48 hours from the treatment. It can beobserved from Figure 4a that vitamin A was not toxic up to a dose of 1 x10-5 M inKG1a cells, and no significant change was observed at 24hours and 48 hours.Therefore, for further experiments 10-5 M concentration of vitamin A was used.Similarly, Figure 4b, shows toxicity assessment of ascorbic acid dosage at theconcentrations of 2μg / ml, 20μg / ml, and 200μg / ml in KG1a cells, and it can beconcluded from Figure 4b that ascorbic acid was not toxic up to a dose 20μg / ml inKG1a cells.
[068] Hence, it can be inferred from Figure 4 that 10-5 M concentration of vitamin A(retinol), and 20μg / ml of vitamin C (ascorbic acid) were used further in theexperiments.Example 4Comet assay
[069] On exposure to the infrared radiations, the cells display DNA damage and forma comet-shaped pattern after electrophoresis due to the migration of damaged DNAfrom the nucleus towards the anode. The said process of migration of damaged DNAis known as comet assay, which is a sensitive method to measure genotoxicity andcytotoxicity of physical and chemical agents. For the purpose of performing the cometassay, 0.5% low melting point agarose (LMPA) was prepared in PBS, and 1% normalmelting point agarose (NMPA) was prepared in distilled water. The low melting pointagarose (LMPA) tube was placed in 37°C water bath to cool and stabilize. The slidesfrosted at one side, were dipped in methanol and burned over a blue flame to removethe machine oil and dust. While normal melting point agarose (NMPA) was hot, slideswere dipped into normal melting point agarose up to 1 / 3th of the frosted area and thengently removed. The underside of the slides was wiped and then dried at 37°C or on100°C hot plate.
[070] In the assay as performed herein, the cells were irradiated at 4Gy in Bhabhatron-II Teletherapy unit (60Co source) at a dose rate of 1.120Gy / min with 80cm source tosample distance and 35x35cm2 field size. After irradiation, the composition of thepresent disclosure was added into culture medium and cells were incubated at 37°C in5% CO2 and humidified atmosphere. After 24 and 48 hours, the cells were analyzedfor comet formation. Approximately 10000 cells were mixed in 100μl or less volumeper 150μl low melting point agarose (LMPA). To the NMPA coated slide, 250μl of lowmelting point agarose containing cells was poured and a uniform layer was made byplacing a coverslip or by spreading with pipette tip over the slide. The prepared slideswere then kept on ice packs until agarose gel hardened. Subsequent steps wereperformed under low light conditions, wherein, the slides were slowly lowered into thecold, freshly made lysis solution for 40-120 minutes at 4°C. After keeping the slides inthe lysis solution, slides were gently removed and placed in the horizontal gelelectrophoresis tank. The buffer reservoir was filled with freshly made electrophoresisbuffer having pH >13, until the buffer level completely covered the slides. The slideswere kept in the alkaline buffer for 20 minutes to allow for the unwinding of the DNAand the exposure of alkali-labile site. Electrophoresis was then performed for 30minutes on ice at 0.74V / cm or 24V and 300mA. The slides were placed in a box andfollowed by coating the slides dropwise with neutralization buffer for 5 minutes. Theslides were drained, and the similar procedure was followed two more times. The slideswere stained with 80μl of 2μg / ml ethidium bromide solution. The slides were incubatedfor 5 minutes and then dipped in chilled distilled water to remove excess stain. Thecoverslip was then placed over it and the slides were scored immediately under thefluorescence microscope (M / s Biorad; Model name: Zoe). The comet images wereanalyzed by CASP and OpenComent softwares. The boxplot was constructed inOriginPro2017 software.
[071] As explained herein, the infrared radiations (IR) damages DNA either directlyor indirectly. In direct interaction, IR generates single and double strand breaks in DNAby energy deposition. The reactive oxygen species (ROS) generation by IR causesDNA damage in indirect interaction. In the present disclosure, the DNA damageoccurred to irradiated KG1a cells was detected in comet assay, where the formation ofcomet by a cell indicated DNA strand breaks formation. The degradation of DNA wasshown as tail of a comet along with the undamaged DNA as a head of a comet as shownin Figure 5a. Different test samples tested for DNA damage under comet assayincluding control, 4Gy of IR, LiCl, ascorbic acid, GR23 peptide, vitamin A, Li-ascorbic acid, Li-GR23, ascorbic acid-GR23, GR23-Vitamin A, Li-GR23-Vitamin A,composition. It is evident from Figure 5 that the 4Gy of infrared exposure to cellscaused maximum damage to DNA among all the test samples, which was significantlyreduced in the presence of composition of the present disclosure as evident from thepercentage (%) of tail DNA in this sample as compared to control. Further, whenascorbic acid was replaced by vitamin A in the composition, no significant differencewas observed in DNA degradation as compared to 4Gy. This indicated that ascorbicacid in the composition is non-replaceable.
[072] Figure 5b of the present disclosure, depicted the box plot of percentage of tailDNA in control, 4Gy IR, LiCl, ascorbic acid, GR23, Vitamin A, Li- ascorbic acid, Li-GR23, ascorbic acid-GR23, GR23-Vitamin A, Li-GR23-Vitamin A, composition ofthe present disclosure. It can be observed from Figure 5b that the compositioncontaining LiCl (at a concentration in the range of 1-20mM), ascorbic acid, and GR23peptide was observed to have significantly decreased comet formation. The decreasein the comet assay indicates the genoprotective effect of the composition.Example 5
[073] Clonogenic assay
[074] The clonogenic assay was performed to study the effectiveness of compositionon the survival and proliferation of cells. For this purpose, the irradiated KG1a cellswere grown in methyl cellulose because of their non-adherence. Further, methylcellulose fixed the cells at a place so that they form clones in-situ. The KG1a cells wereirradiated at 4Gy and then 1 X 10^3 of the said KG1a cells were counted and mixed with4.5ml of 2.5% methyl cellulose, 10% FBS, 2mM LiCl, 20μg ascorbic acid, and 2.5μMGR23 in a treatment group while in another group ascorbic acid was replaced with1x10-5M Retinol. The mixing tube was vortexed to mix the contents thoroughly andthen subjected to incubation at room temperature for 5 minutes to allow bubbles to riseto the top. Methyl cellulose and cell mixture were dispensed into 35mm culture dishes.The culture plates were then incubated for 12 days at 37°C in 5% CO2 atmosphere with>95% humidity. Colonies were counted using an inverted microscope. Further, DoseModification Factor (DMF) and Do were calculated. Do indicates the radiation dose inGray at which 37% cell survival was observed. It is calculated by the slope of semi-logplot of irradiated KG1a cells. Dose Modification Factor (DMF) is the factor by whichthe treatment increases the radiotolerance of irradiated cells and is expressed as theratio of Do of the Treatment / Do of the Control.
[075] In order to estimate Do and dose modification factor (DMF), the platingefficiency and surviving fractions were calculated using the formulas as followed:
[076] Plating efficiency (PE) = number of colonies counted / number of cells plated x100
[077] Surviving fraction = PE of treated sample / PE of control sample x 100
[078] In the results of the clonogenic assay, the treatment of cells with compositionof the present disclosure were found to have significantly improved surviving fractionof cells at 4Gy. Figure 6 shows the semi-log plot of irradiated KGla cells treated withvarious compositions: (i) Composition of the present disclosure (Li+GR23+AA); (ii)Composition II (Li+GR23+Vitamin A); and (iii) control. The D37 i.e., radiation dose atwhich 37% cell survival of KG1a cells was observed, increased from 1.415Gy to2.05Gy. The treatment of cells with composition of the present diclosure(Li+GR23+AA) significantly improved the surviving fraction of cells at 4Gy, byapproximately two-fold change. The DMF of cells at this dose was calculated to be1.448 for 37% surviving cells. However, it was observed that on replacing ascorbicacid in the composition with vitamin A, the D37 was calculated to be 1.612Gy, and itcan be inferred that there was not much improvement in cell proliferation.
[079] It can concluded that the KGla cells treated with composition of the presentdisclosure possess maximum surviving fraction among all test samples including,composition II (Li+GR23+Vitamin A), and control.
[080] It can also be inferred that the presence of ascorbic acid in the composition isvery crucial for arriving at the composition with the desired effect. Replacing ascorbicacid with any other component, such as vitamin A does not exhibit the desired effectin terms of cell proliferation.Example 6Survivability of irradiated BALB / c mice
[081] In the present example, the in-vivo experiment was performed to study theeffect of composition by assessing survivability of lethally irradiated BALB / c miceupon IR exposure. Mice were exposed to 7.5Gy dose of IR in 60C gamma chamber(Cobalt Teletherapy Bhabhatron-II) at a dose rate of 1.158Gy / min at 80cm sample tosource distance in a 35x35cm2 field size. Radiation dose calibration was done byFricke's dosimetry method. Post irradiation, the composition was injectedintraperitoneally to the test mice for 4-5 days. The survival and weight of mice wasrecorded up to 30 days. As shown in Figure 7, the IR exposed mice showed 25%survival after 15 days, whereas when mice were treated with the composition of thepresent disclosure, no causality was observed in said mice throughout the period ofexperimentation. Alongside, regain of initial loss in weight after IR exposure wasobserved. Therefore, the results indicate that the composition of the present disclosureis a potential radio-mitigator under in-vivo conditions.Example 7Scanning electron microscopy
[082] KG1a cells were used to standardize the coating of cells by alginate andfibronectin conjugate (AF) due to the presence of cell surface markers which aresimilar to hematopoietic stem cells. In addition, homogeneity of KG1a cells allowedto measure the size of cells after coating. Briefly, cells growing in the log phase werewashed with phosphate buffered saline (PBS) and resuspended in 100μl of PBS,followed by the addition of 100μl of alginate and fibronectin conjugate and furtherincubation for 20 minutes at room temperature. After incubation, the cells were fixedin 1% paraformaldehyde for 20 minutes at 4°C. For each sample prepared, a smearwas made on the glass coverslip and allowed to air dry. To ensure completedehydration, ethanol was used in increasing concentrations like 35%, 40%, 50%, 60%and 70% onto glass coverslip to avoid cell rupturing. After drying, specimens werethen observed at 40X for cell shape and integrity. All specimens were mounted onthe specimen holder securely with the help of carbon tape. The specimen holder wasthen subjected to gold plating with the help of an ion milling system. The preparedspecimens were then mounted on the microscope and observed at variousmagnifications.
[083] Referring to Figure 8, it can be observed that the KG1a cells coated withalginate and fibronectin conjugate did not show an increase in their size andmaintained uniformity in their shape. Change in cell surface morphology from granularto smooth was observed after cell coating, which clearly depicts the SEM micrographsof KGla cells and AF conjugated KGla cells at 10X and 40X magnifications.Example 8Homing of alginate and fibronectin conjugate (AF) coated cells
[084] The composition of the present disclosure was further evaluated for improvingbone marrow engraftment by sequential administration of its constituents. In case ofradiation injury, bone marrow transplantation is the only established procedure whenaplasia endangers life due to opportunistic infections. Nevertheless, dearth of growthfactors produced by cells ensuing aplasia, causes cell death and decrease engraftmentof stem cells in the bone marrow. Successful engraftment of stem cells in bone marrowknown as homing, is a prerequisite for the repopulation of hematopoietic system. Inaddition, the transplanted stem cells en route to bone marrow gets differentiated withinblood stream, thereby losing their pluripotency. In order to maintain stemness andensure their targeted delivery to bone marrow, an alginate and fibronectin (AF)conjugate was prepared. AF shielded bone marrow cells were used in the presentdisclosure for targeting the bone marrow, that decreased the stem cell maturation withinthe blood stream before homing. Before entering into the bone marrow, the alginateand fibronectin coat of infused stem cells was removed by the free fibronectin beingsecreted by the endothelial cells and bone marrow stromal cells. In addition, matrixmetalloproteinase (MMP), especially MMP-2 and MMP-9 present in the bone marrow,degrades fibronectin moiety of the alginate and fibronectin conjugate. For thedegradation of fibronectin conjugated alginate, the anti-oxidant potential of ascorbicacid was used, which degraded the alginate circulating in the blood stream in theaftermath of cell's deshielding.
[085] The bone marrow cells were isolated from the sacrificed mice and diluted in3ml of phosphate buffered saline. In a 15ml conical bottom tube, 3ml of Histopaque1077 (M / s Sigma) was taken and 3ml of diluted bone marrow cells were layered on it.Further, the mix in the conical bottom tube was subjected to centrifugation at 4000rpmfor 20 minutes in a swing out rotor. The mononuclear cells (MNC) ring was isolatedand washed with 5ml phosphate buffered saline. After washing, the MNC wereresuspended in Dulbecco's Modified Eagle's Medium (DMEM with 10% Fetal BovineSerum) and given 2mM LiCl treatment for 1 hour. The cells in the amount of 1x105were then mixed with alginate and fibronectin conjugate (AF) in 1:1 (v / v) ratio for cellshielding. The coating was allowed for 20 minutes at room temperature, subsequentlycells were injected into the mice through lateral tail vein.
[086] For the confirmation of homing of alginate and fibronectin conjugate (AF)coated cells, a test mice were sacrificed by cervical dislocation under anesthesia andbone marrow cells were collected by flushing femur bone with phosphate bufferedsaline (PBS). The bone marrow cells were labelled with cell membrane labelling dye,PKH green, by following the manufacturer's instructions (M / s Sigma). For PKHlabelling, 1.6x10^5 cells were suspended in 25μl of phosphate buffered saline and madeup to 1ml with Diluent A (M / s Sigma). PKH green dye in the amount of 4x10 -6 M wasresuspended in 1ml of Diluent A. The prepared 1ml cell mix containing cells, PBS andDiluent A was then mixed with 1ml of diluted PKH dye. The mixture was thenincubated at 25°C for 2-5 minutes with intermittent mixing by inverting. Further to stopthe reaction, 2ml of fetal bovine serum (FBS) was added into the mixture and incubatedfor 1 minute. The mixture obtained was diluted with 4ml of Iscove's ModifiedDulbecco's Medium (IMDM with 10% FBS) and centrifuged at 400g for 10 minutes.The labelled cells were then washed three times with 10ml of IMDM and subsequentlyfluorescence was observed under microscope.
[087] After confirming cells labeling, PKH stained cells were coated with 100μl ofalginate and fibronectin conjugate (AF) for 20 minutes. These coated cells wereinjected into Balb / C mice through lateral tail vein. After 24 hours, bioluminescenceimaging (BLI) of whole body was performed. Subsequently, mice were sacrificed tocollect femur bone for bioluminescence imaging. The bone marrow was then flushedout of femur bone in phosphate buffered saline in a petridish and were fixed in 1%paraformaldehyde followed by analysis through fluorimetry. The control in thefluorometric analysis indicated the cells reaching to bone marrow without anytreatment.
[088] To check whether coated cells are more targeted towards bone marrow, miceBM cells were pre-labelled with PKH green dye before transplanting into mice. Asignificantly higher number of coated cells were able to reach bone marrow after 24hours of transplantation as observed in bioluminescence imaging of femur and bonemarrow as shown in Figure 9. Figure 9a depicts the images of green coloured bonemarrow cell membrane and blue coloured nucleus showing successful labelling withPKH green dye and 4',6-diamidino-2-phenylindole (DAPI) respectively. Figure 9bdepicts the bioluminescence imaging of the femur bone that was isolated to check PKHfluorescence emanating from bone marrow after 24 hours of cell transplantation.Comparative images of femur bone were developed for bone marrow cells stained withPKH alone, bone marrow cells with alginate and fibronectin conjugate (AF) stainedwith PKH, and the control. Further, as shown in Figure 9c, the fluorometric analysisindicated significantly higher number of alginate and fibronectin coated cells reachingto bone marrow in comparison to cells without coating and the control, respectively. Itcan be appreciated that the PKH-alginate and fibronectin coating improves the chancesof stem cell engraftment in BM which is an essential factor for maintaining stem cellpool. Therefore, the said pool would, consequently, give rise to matured blood cells togenerate immunity and prevent opportunistic infections from radiation injuries.Example 9Bone marrow engraftment
[089] The sign and symptoms of acute bone marrow syndrome induced by radiationinclude, damage to lymphatic system, nausea, diarrhea, infection and bleeding. Theseverity of damage depends upon the dose, and if not treated promptly, causes death.So, immediate bone marrow transplantation and other protective measures are requiredin case of aplasia consequent to IR exposure. Therefore, in the present examplesequential administration of the components of the composition was tested for theeffectiveness of composition for treating injuries.
[090] In the present experiment, the animals were divided into five groups, with 5-6animals in each group viz. control group, 7.5Gy irradiated group, bone marrowtransplantation group (BMT) group, alginate and fibronectin conjugate (AF) coatedbone marrow transplantation group (BMT) group and LiCl+GR23+AF coated BMTgroup. In the first step, 2mM LiCl and 3-7mg / kg body weight of mice GR23 wereinjected intraperitoneally and bone marrow transplantation was performed throughlateral tail vein. Further, LiCl was injected 1 hour prior to infrared exposure, followedby injecting GR23 immediately after the infrared exposure. Bone marrowtransplantation group (BMT) for 1x10^6cells / 200μl PBS was performed after 24 hoursof infrared exposure, followed by administration of 250mg / 100ml ascorbic acid(having pH of 3.5) to mice ad libitum. Post infrared exposure, the animals weredissected after 5 days, 10 days and 60 days, respectively. Approximately 50μl of bloodwas collected in tubes coated with 10% EDTA from each animal for hematologicalanalysis at different time interval. Blood sample was aspirated in NIHON KOHDEN(Model: MEK-6450k) haematology analyzer to measure blood parameters. Figure 10of the present disclosure depicts the timeline of the sequential administration events ofcomposition constituents for enhancing bone marrow engraftment.
[091] As shown in Figure 11a of the present disclosure, the survival and weight of themice were monitored for 30 days post treatment, wherein, 7.5Gy infrared exposure waslethal for BALB / c strain. Therefore within 12 days, 100% lethality was observed in theirradiated group. Mice treated with only bone marrow transplantation and exposed to7.5Gy infrared exposure also met with a similar fate. Mice, which were transplantedwith alginate and fibronectin conjugate (AF) coated bone marrow cells, showed 25%survival. It is noteworthy to mention here that mice receiving the composition of thepresent disclosure along with the 7.5Gy infrared exposure showed 100% survival evenafter 30 days. With an initial decrease in weight of these mice up to 9 days, the miceinjected with disclosed composition of the present disclosure showed improvement intheir growth, similar to control mice. Hence, it can be conluded that the compositionof the present disclosure helps in overcoming the radiation effects. On the other hand,irradiated mice; bone marrow transplanted mice; and alginate and fibronectinconjugate (AF) coated bone marrow transplanted mice, showed a sudden decrease intheir weight, indicating radiation sickness.
[092] It is evident from Figure 11b that mice receiving multi-therapy treatment withcomposition of the present disclosure did not show any abnormal growth up to 90 daysindicating non-tumorigenicity of the followed regimen.
[093] These results indicate the potential of the composition of the present disclosurein improving stem cell transplantation efficiency.Example 10Histological assessment
[094] The radiation exposure kicks in various problems and diseases which might bedeveloped specifically in the organs exposed or the whole body. The sign andsymptoms associated with the gastrointestinal (GI) syndrome occur due to depletion ofthe intestinal mucosa and the bone marrow. GI syndrome includes abrupt loss ofappetite, gastric complaints, apathy, generally followed by nausea and vomiting whichmay turn to severe dehydration, haemoconcentration and circulatory collapse leadingto cell death. Histological assessment was performed in the present example to studythe effects of the composition of the present disclosure against control in the individualorgans of irradiated mice samples.
[095] a) Processing and block preparation: For the present experiment, the bodyorgans including jejunum, lungs, liver and kidney were harvested from BalB / C miceand were fixed in 4% formalin for 20 minutes at room temperature for 24 hours. Organswere then sequentially transferred to 70%, 80% and 100% alcohol for 30 minutes forcomplete dehydration. The dehydrated organs were then transferred to 20:100 ratio ofxylene and hot wax solution and incubated for 2 hours at 60°C. The incubated organtissues were embedded in paraffin wax in a histological cassette. Paraffin blocks werethen cut into 3-5μm serial sections using microtome which was transferred immediatelyin 60°C water to straighten the ribbon or cut section. Subsequently, cut section wasplaced on a glass slide coated with 0.1% poly-L-lysine or egg albumin.
[096] b) Hematoxylin and Eosin staining: The cut-sections prepared in step (a) ofthe present example were further incubated in 100% xylene for 3 minutes repeatedlyfor three times. The incubated sections were then kept in 1:1 mixture of xylene and100% ethanol for 3 minutes followed by dipping in 95% ethanol two times for 3minutes each. The cut sections after dipping in ethanol were washed twice with 70%and 30% ethanol and then with distilled water for 2-3 times. The slides were incubatedin Hematoxylin (Gills 1X) for 30 minutes and then rinsed under tap water until theexcess stain starts to drain out. Further, the slides were dunked 2-3 times in 1% HCl in70% ethanol until the sections turned pink. The slides were rinsed with tap water for 2-3 minutes, then slowly dipped in 2% ammonia water for 2-3 times. Subsequently, slideswere rinsed again with tap water for 2-3 times and then incubated in 1% Eosin for 30-60 seconds. Slides were further rinsed with tap water containing 30% ethanol and thensubjected to serial incubation in 95% and 100% alcohol for 2 minutes for 3 times ineach solution. The slides were then transferred in 1:1 solution of xylene and 100%methanol for 2 minutes. Subsequently, the slides were dipped in 100% xylene for 2minutes for 3 times and then mounted by coverslip using permount / xylene basedmounting medium.
[097] As shown in Figure 12a, histology of mice exposed to 7.5Gy IR showeddenudation of villi forming the intestinal mucosa after 5 days. The length of villi wasalso observed to be decreased in the tissue section. After 5 days, similar changes wereobserved in the mice given sequential treatment. However, after 10 days the villiseemed to be repaired re-forming the intestinal mucosa as shown in Figure 12b. It canbe inferred nfrom Figure 12 that after 60 days, complete rejuvenation of intestinalmucosa took place in the animals of sequential treatment group. However, all untreatedmice died within 12 days of infrared exposure.
[098] Liver is a highly radioresistant organ and its response to radiation is known asradiation hepatitis. It is characterized by severe sinusoidal congestion, hyperemia / haemorrhage, some atrophy of the central hepatic cells and mild dilation of centralveins. Fatty liver changes with decrease in the sinusoidal spaces were observed after7.5Gy of IR exposure in animals as depicted in Figure 12a and Figure 12b. Further,referring to Figure 12c , it can be observed that the sequential treatment showed returnof normal histological characteristics of the liver after 60 days of survival.
[099] The radiation response of the respiratory system is called as radiationpneumonitis. It is an inflammatory reaction which may recover or may lead to chroniclung fibrosis. It is characterized by the accumulation of fibrin-rich exudates withinalveoli, the thickening of alveolar septa by fibrillar material and cellular proliferation.The fibrin condenses at the alveolar wall to produce hyaline membrane. In the presentexperiment, mice exposed to 7.5Gy infrared radiation showed collapse of bronchiolesand alveolar spaces in lungs as depicted in Figure 12a and Figure 12b. Inflammatoryinfiltration of cells was also observed within lung spaces. However, it can be observedfrom Figure 12c that the sequential treatment mice showed overcoming of thesesymptoms after 60 days of survival.
[100] Kidney is a moderately radiosensitive organ. Radiation response of the kidneyis called radiation nephritis, which occurs 6 months to 1 year after the completion ofradiation (for e.g., in radiotherapy). It is characterized by swelling of legs, shortness ofbreath, headache and vomiting. However, in the present experiment, no significantchange was observed in any group of mice as depicted in Figure 12a, Figure 12b andFigure 12c of the present disclosure. The histological characteristics also indicated theabsence of treatment induced nephrotoxicity in the mice receiving sequential treatmentof individual component of disclosed composition.
[101] c) Hematological parameters: Irradiation causes initial granulocytosis within2-4 days after radiation exposure, followed by leucopenia during the 4th and 5th weeks.A "late critical phase" is characterized by a severe granulocytopenia andthrombocytopenia. This phase is initiated by nausea, vomiting, fever, and diarrhoea.About 50% of Hiroshima and Nagasaki population with bone marrow syndrome diedduring this phase. The survival of the exposed individual depends upon the recovery ofthe bone marrow. Figure 13 depicts the record of various blood parameters in irradiatedmice samples on 5th, 10th, 30th and 60th day post infrared exposure. The said bloodparameters included WBC: white blood cell count (x10^3 / mm3); RBC: red blood cellcount (x10^3 / mm3); HGB: haemoglobin concentration (g / dl); HCT: haematocrit (%);MCV: mean cell volume (fL); MCH: mean cell haemoglobin (pg); MCHC: mean cellhaemoglobin concentration (g / dl); PLT: platelet count (x10^3 / μl); LY%: lymphocyte(%); and GR%: granulocyte (%), respectively. It can be observed from Figure 13 thatthe irradiated mice after 5 days showed a complete absence of lymphocytes andgranulocytes in all treatment groups. The ensuing aplasia is responsible foropportunistic infection and requires repeated blood transfusion due to decreasedplatelet count. After 10 and 30 days of infrared exposure, the granulocytes andlymphocytes population in the sequential treatment group subsequently revived. After60 days, complete reconstitution of the hematopoietic compartment was observed inthe mice receiving sequential treatment of individual components of the compositionof the present disclosure as depicted in Figure 13.
[102] Overall, it can be observed that the presence of the three components: (a)lithium chloride having a concentration in the range of 1-20 mM with respect to thecomposition; (b) a peptide having an amino acid sequence as set forth in SEQ ID NO:1; and (c) ascorbic acid, is crucial for arriving at the composition of the presentdisclosure. The presence of the aforementioned components exhibits a synergisticeffect in mitigating the effects of nuclear radiation. Replacing any one of theaforementioned components with any other component, for instance, replacingascorbic acid with retinoic acid, would not give the desired effect. The composition ofthe present disclosure decreases radiation injury in-vitro and in-vivo by improvinghematopoietic cells survival. Further, the composition of the present disclosurefacilitated homing of cells to bone marrow, their self-renewal, proliferation anddifferentiation, indicating its potential to enhance bone marrow transplantation and tomitigate the radiation injury.Advantages of the present disclosure
[103] The present disclosure discloses a composition comprising lithium chloridehaving a concentration in the range of 1-20 mM with respect to the composition , GR23peptide (SEQ ID NO:1), and ascorbic acid for treating radiation injuries in the exposedindividual. The composition of the present disclosure exhibits a synergistic effect inmitigating the damage caused by radiation, and also in facilitating homing of cells tobone marrow, their self-renewal, proliferation and differentiation. The composition isalso useful in the event of undesired radiation exposure due to radiological attack,nuclear disaster, and patients undergoing radiation therapy and bone marrowtransplantation. The blood forming stem cells or hematopoietic stem cells reside in thebone marrow which upon infrared exposure undergo cell death / apoptosis due to DNAdamage. Therefore, by improving hematopoietic cell survival, the present disclosureprovides an effective technique for the treatment of radiation injuries. Further, thecomposition as disclosed herein decreases radiation injury by enhancing the cellsurvival acquired by decreasing DNA degradation and enhanced clonogenicity.Therefore, the composition of the present disclosure acts as a safe and potentialmolecule for protecting bone marrow stem cells. Moreover, the sequentialadministration of individual components, such as lithium chloride (LiCl), GR23(peptide having SEQ ID NO: 1), and ascorbic acid, is used in the cell transplantationstudies for enhancement in bone marrow reconstitution after radiation apalasia.
Claims
1. A composition comprising: (a) lithium chloride having a concentration in the range of 1-20 mM with respect to the composition; (b) a peptide having an amino acid sequence as set forth in SEQ ID NO: 1; and (c) ascorbic acid.
2. The composition as claimed in claim 1, wherein lithium chloride is having a concentration in the range of 2-15 mM with respect to the composition.
3. The composition as claimed in claim 1, wherein the peptide is having a concentration in the range of 1-30 μM with respect to the composition.
4. The composition as claimed in claim 3, wherein the peptide is having a concentration in the range of 1.5-20 μM with respect to the composition.
5. The composition as claimed in claim 1, wherein ascorbic acid is having a concentration in the range of 0.05M-1M with respect to the composition.
6. The composition as claimed in claim 5, wherein ascorbic acid is having a concentration in the range of 0.1M-0.5M with respect to the composition.
7. A process for preparing the composition as claimed in claim 1, said process comprising: contacting lithium chloride having a concentration in the range of 1-20 mM with respect to the composition, the peptide, and ascorbic acid, to obtain the composition.
8. The process as claimed in claim 7, wherein contacting lithium chloride having a concentration in the range of 1-20 mM with respect to the composition, the peptide, and ascorbic acid is done at a temperature in the range of 2-6ºC to obtain the composition.
9. The composition as claimed in claim 1, wherein the composition mitigates the effect of nuclear radiation.
